We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Blocking Phosphatidylcholine Synthesis Lowers Levels of Circulating Lipids in Mouse Hyperlipidemia Model

By LabMedica International staff writers
Posted on 21 Sep 2015
Print article
Image: A four milliliter sample of hyperlipidemic blood with lipids separated into the top fraction (Photo courtesy of Wikimedia Commons).
Image: A four milliliter sample of hyperlipidemic blood with lipids separated into the top fraction (Photo courtesy of Wikimedia Commons).
Cardiovascular disease researchers seeking new ways to treat hyperlipidemia found that inhibition of the gene encoding a protein required for biosynthesis of phosphatidylcholine, a major cell membrane component, in a mouse model resulted in decreased levels of lipids (cholesterol, triglyceride, and phospholipid) in circulation.

Investigators at SUNY Downstate Medical Center (Brooklyn, NY, USA) genetically engineered a line of C57BL/6J mice to lack the gene for production of the enzyme LPCAT3 (Lysophosphatidylcholine acyltransferase 3), which is involved in the synthesis of the cell membrane lipid phosphatidylcholine (PC).

The investigators reported in the July 28, 2015, online edition of the journal Gastroenterology that knock-out (KO) mice lacking the LPCAT3 gene survived only three weeks after birth. Oil Red O staining showed that the controls, but not LPCAT3 KO mice, accumulated lipids in the small intestine.

Oral administration of PC and olive oil allowed the LPCAT3 KO mice to survive, with the same body weights as controls, but the KO mice had shorter and wider small-intestinal villi and longer and bigger small intestines. These modifications were associated with reduced intestinal uptake of lipid by the small intestine and reduced plasma levels of cholesterol, phospholipid, and triglyceride.

"Hyperlipidemia, or high levels of lipids, is a common disease and contributes significantly to cardiac related morbidity and mortality," said senior author Dr. Xian-Cheng Jiang, professor of cell biology at SUNY Downstate Medical Center. "Statin drug trials have provided the major evidence for the benefits of a therapy that lowers low density lipoprotein (LDL), the so called "bad cholesterol", and statin therapy is now the mainstay of clinical management of cardiovascular disease. However, there are many instances in which patients do not respond to or cannot tolerate statins. Our study is intended to provide a novel approach to reduce the "bad" lipids in the blood. Although the study was conducted in a mouse model, the outcomes may be applicable to humans."

Related Links:

SUNY Downstate Medical Center


New
Gold Supplier
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
New
Lateral Flow Test Reader
BSX READER
New
COVID-19 Antigen Rapid Test
CareStart COVID-19 Antigen Rapid Test
New
SARS-CoV-2 Antibody Test
Finecare 2019-nCoV Antibody Test

Print article
Mayo Medical Laboratories
BIOHIT  Healthcare OY

Channels

Pathology

view channel
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion... Read more

Industry

view channel
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)

Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.